Skip to main content
Top
Published in: International Urology and Nephrology 6/2022

01-06-2022 | Prostatitis | Urology - Original Paper

RETRACTED ARTICLE: Morphological study of chronic prostatitis–chronic pelvic pain syndrome (CP/CPPS) normal modeling dose of T2 peptide in mice

Authors: Maladho Tanta Diallo, Muhammad Ali, Qi Zhang, Yang Wang, Ziyang Long, Jianyue Ding, Cangyuan Zhang, Xiaodong Zhu, Mingrui Jiang, Qiannan Sun, Xiaohui Zhou, Daorong Wang

Published in: International Urology and Nephrology | Issue 6/2022

Login to get access

Abstract

Objectives

However, the pathogenesis and etiology of CP/CPPS are still poorly understood. Therefore, there is a need for further research through the Image J software to develop models capable of imitating the pathogenesis and etiology of CP/CPPS with different doses of the pathogenesis and the etiology of CP/CPPS is still poorly understood. The aim was to determine the area of the prostatic interstitium, the localization of the inflammation, and the impact of different doses on the group model.

Materials and methods

A total of 30 male ICR mice were randomly grouped into 5 (n = 6): 45 μg group = 6, 60  μg group = 6, 90  μg group = 6, 120  μg group = 6, 120  μg group = 6, control group = 6. With the exception of the control group, all the groups were immunized by injecting 0.2 mL of T2 peptide emulsion and immune adjuvant CFA to induce non-bacterial chronic prostatitis on days 0 and 14 of the mice and finally executed on day 28. All injections were administered subcutaneously. HE staining was used to evaluate changes in prostate pathology. Image J was used to calculate the area of the prostate interstitium, which represents the degree of prostate edema. To compare statistical differences between groups, the ANOVA test was used.

Results

From the perspective of pathological scoring, the 60 μg, 90  μg, and 120  μg groups had the highest scores using Image J to treat inflammatory cells. In addition, in the prostate interstitium area treated, it was found that the 90  μg group attained the largest prostate interstitial area as well as the highest degree of swelling.

Conclusions

From the results, Image J software is an effective tool in the calculating the surface of the prostatic interstitium and the specific localization of the inflammation.
Literature
1.
go back to reference Roberts RO et al (1998) Prevalence of a physician-assigned diagnosis of prostatitis: the Olmsted County Study of Urinary Symptoms and Health Status Among Men. Urology 51(4):578–584CrossRefPubMed Roberts RO et al (1998) Prevalence of a physician-assigned diagnosis of prostatitis: the Olmsted County Study of Urinary Symptoms and Health Status Among Men. Urology 51(4):578–584CrossRefPubMed
2.
go back to reference Collins MM et al (1998) How common is prostatitis? A national survey of physician visits. J Urol 159(4):1224–1228CrossRefPubMed Collins MM et al (1998) How common is prostatitis? A national survey of physician visits. J Urol 159(4):1224–1228CrossRefPubMed
3.
go back to reference Habermacher GM, Chason JT, Schaeffer AJ (2006) Prostatitis/chronic pelvic pain syndrome. Annu Rev Med 57:195–206CrossRefPubMed Habermacher GM, Chason JT, Schaeffer AJ (2006) Prostatitis/chronic pelvic pain syndrome. Annu Rev Med 57:195–206CrossRefPubMed
4.
go back to reference Wenninger K et al (1996) Sickness impact of chronic nonbacterial prostatitis and its correlates. J Urol 155(3):965–968CrossRefPubMed Wenninger K et al (1996) Sickness impact of chronic nonbacterial prostatitis and its correlates. J Urol 155(3):965–968CrossRefPubMed
5.
go back to reference Thakkinstian A et al (2012) α-blockers, antibiotics and anti-inflammatories have a role in the management of chronic prostatitis/chronic pelvic pain syndrome. BJU Int 110(7):1014–1022CrossRefPubMed Thakkinstian A et al (2012) α-blockers, antibiotics and anti-inflammatories have a role in the management of chronic prostatitis/chronic pelvic pain syndrome. BJU Int 110(7):1014–1022CrossRefPubMed
7.
go back to reference Ku JH, Paick JS, Kim SW (2005) Chronic prostatitis in Korea: a nationwide postal survey of practicing urologists in 2004. Asian J Androl 7(4):427–432CrossRefPubMed Ku JH, Paick JS, Kim SW (2005) Chronic prostatitis in Korea: a nationwide postal survey of practicing urologists in 2004. Asian J Androl 7(4):427–432CrossRefPubMed
8.
go back to reference Schaeffer AJ et al (2003) Summary consensus statement: diagnosis and management of chronic prostatitis/chronic pelvic pain syndrome. Eur Urol Suppl 2(2):1–4CrossRef Schaeffer AJ et al (2003) Summary consensus statement: diagnosis and management of chronic prostatitis/chronic pelvic pain syndrome. Eur Urol Suppl 2(2):1–4CrossRef
9.
go back to reference Tyagi P et al (2015) Mp25-07 prostatic inflammation evokes upregulation of neurotrophins in sensory ganglia: possible contribution to dysfunctional voiding. J Urol 193(4S):e287–e287CrossRef Tyagi P et al (2015) Mp25-07 prostatic inflammation evokes upregulation of neurotrophins in sensory ganglia: possible contribution to dysfunctional voiding. J Urol 193(4S):e287–e287CrossRef
10.
go back to reference Ludwig M et al (2001) Immunocytological analysis of leukocyte subpopulations in urine specimens before and after prostatic massage. Eur Urol 39(3):277–282CrossRefPubMed Ludwig M et al (2001) Immunocytological analysis of leukocyte subpopulations in urine specimens before and after prostatic massage. Eur Urol 39(3):277–282CrossRefPubMed
11.
go back to reference Batstone G, Doble A, Gaston J (2002) Autoimmune T cell responses to seminal plasma in chronic pelvic pain syndrome (CPPS). Clin Exp Immunol 128(2):302–307CrossRefPubMedPubMedCentral Batstone G, Doble A, Gaston J (2002) Autoimmune T cell responses to seminal plasma in chronic pelvic pain syndrome (CPPS). Clin Exp Immunol 128(2):302–307CrossRefPubMedPubMedCentral
12.
go back to reference Kouiavskaia DV et al (2009) T-cell recognition of prostatic peptides in men with chronic prostatitis/chronic pelvic pain syndrome. J Urol 182(5):2483–2489CrossRefPubMedPubMedCentral Kouiavskaia DV et al (2009) T-cell recognition of prostatic peptides in men with chronic prostatitis/chronic pelvic pain syndrome. J Urol 182(5):2483–2489CrossRefPubMedPubMedCentral
13.
go back to reference Wang W et al (2018) Experimental rodent models of chronic prostatitis and evaluation criteria. Biomed Pharmacother 108:1894–1901CrossRefPubMed Wang W et al (2018) Experimental rodent models of chronic prostatitis and evaluation criteria. Biomed Pharmacother 108:1894–1901CrossRefPubMed
14.
go back to reference Khan FU et al (2017) A novel mouse model of chronic prostatitis/chronic pelvic pain syndrome induced by immunization of special peptide fragment with aluminum hydroxide adjuvant. Immunol Lett 187:61–67CrossRefPubMed Khan FU et al (2017) A novel mouse model of chronic prostatitis/chronic pelvic pain syndrome induced by immunization of special peptide fragment with aluminum hydroxide adjuvant. Immunol Lett 187:61–67CrossRefPubMed
16.
go back to reference Tang M et al (2019) Effect of oral T2 antigen on chronic prostatitis/chronic pelvic pain syndrome in mice model. Inflammation 42(6):2086–2094CrossRefPubMed Tang M et al (2019) Effect of oral T2 antigen on chronic prostatitis/chronic pelvic pain syndrome in mice model. Inflammation 42(6):2086–2094CrossRefPubMed
17.
go back to reference Cheng Y et al (2019) Novel treatment of experimental autoimmune prostatitis by nanoparticle-conjugated autoantigen peptide T2. Inflammation 42(3):1071–1081CrossRefPubMed Cheng Y et al (2019) Novel treatment of experimental autoimmune prostatitis by nanoparticle-conjugated autoantigen peptide T2. Inflammation 42(3):1071–1081CrossRefPubMed
18.
go back to reference Wang W et al (2019) Morphological reseach on expression of inflammatory mediators in murine models of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) induced by T2 antigen. Andrologia 51:11CrossRef Wang W et al (2019) Morphological reseach on expression of inflammatory mediators in murine models of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) induced by T2 antigen. Andrologia 51:11CrossRef
19.
go back to reference Cao Y et al (2019) A nanoparticle-coupled T2 peptide induces immune tolerance and ameliorates chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) in mice model. Fund Clin Pharmacol 33(3):267–276CrossRef Cao Y et al (2019) A nanoparticle-coupled T2 peptide induces immune tolerance and ameliorates chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) in mice model. Fund Clin Pharmacol 33(3):267–276CrossRef
20.
go back to reference Wang W et al (2019) Morphological reseach on expression of inflammatory mediators in murine models of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) induced by T2 antigen. Andrologia 51(11):e13435CrossRefPubMed Wang W et al (2019) Morphological reseach on expression of inflammatory mediators in murine models of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) induced by T2 antigen. Andrologia 51(11):e13435CrossRefPubMed
21.
go back to reference Keetch DW, Humphrey P, Ratliff TL (1994) Development of a mouse model for nonbacterial prostatitis. J Urol 152(1):247–250CrossRefPubMed Keetch DW, Humphrey P, Ratliff TL (1994) Development of a mouse model for nonbacterial prostatitis. J Urol 152(1):247–250CrossRefPubMed
22.
go back to reference Rivero VE et al (1998) Non-obese diabetic (NOD) mice are genetically susceptible to experimental autoimmune prostatitis (EAP). J Autoimmun 11(6):603–610CrossRefPubMed Rivero VE et al (1998) Non-obese diabetic (NOD) mice are genetically susceptible to experimental autoimmune prostatitis (EAP). J Autoimmun 11(6):603–610CrossRefPubMed
Metadata
Title
RETRACTED ARTICLE: Morphological study of chronic prostatitis–chronic pelvic pain syndrome (CP/CPPS) normal modeling dose of T2 peptide in mice
Authors
Maladho Tanta Diallo
Muhammad Ali
Qi Zhang
Yang Wang
Ziyang Long
Jianyue Ding
Cangyuan Zhang
Xiaodong Zhu
Mingrui Jiang
Qiannan Sun
Xiaohui Zhou
Daorong Wang
Publication date
01-06-2022
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 6/2022
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-022-03185-6

Other articles of this Issue 6/2022

International Urology and Nephrology 6/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.